MERIDIAN BIOSCIENCE INC (VIVO) Stock Analyst Ratings

USA • Nasdaq • NASDAQ:VIVO • US5895841014

33.97 USD
0 (0%)
At close: Jan 30, 2023
33.99 USD
+0.02 (+0.06%)
After Hours: 1/30/2023, 8:27:46 PM
Buy % Consensus

43

ChartMill assigns a Buy % Consensus number of 43% to VIVO. The Buy consensus is the weighted average rating of the current analysts ratings.

  • Analysts have set a mean price target forecast of 34.68. This target is 2.09% above the current price.
  • VIVO was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about VIVO.
  • In the previous month the buy percentage consensus was at a similar level.
  • VIVO was analyzed by 6 analysts. More opinions would make the average more meaningful.
VIVO Historical Analyst RatingsVIVO Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -74 -67 -60 -53 -46 -39 -32 -25 -18 -11 -4 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 33.9734.3434.6834.6835.70 - 1.09% 2.09% 2.09% 5.09%
VIVO Current Analyst RatingVIVO Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5
Up and Down Grades
Date Firm Action Rating
2022-07-08 HC Wainwright & Co. Downgrade Buy -> Neutral
2022-02-07 HC Wainwright & Co. Maintains Buy
2021-11-15 HC Wainwright & Co. Maintains Buy
2021-08-09 HC Wainwright & Co. Maintains Buy
2021-05-10 HC Wainwright & Co. Maintains Buy
2021-02-24 HC Wainwright & Co. Maintains Buy
2021-02-08 HC Wainwright & Co. Maintains Buy

MERIDIAN BIOSCIENCE INC / VIVO FAQ

What do analysts expect the price target to be for MERIDIAN BIOSCIENCE INC (VIVO)?

6 analysts have analysed VIVO and the average price target is 34.68 USD. This implies a price increase of 2.09% is expected in the next year compared to the current price of 33.97.


How do analysts rate MERIDIAN BIOSCIENCE INC (VIVO)?

The consensus rating for MERIDIAN BIOSCIENCE INC (VIVO) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.